BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Annexon\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Annexon\, Inc.'s drugs run\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07020819-10858@assetmemo.bio
DTSTAMP:20261121T010139Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:tanruprubart: Phase 3 readout est. (NCT07020819)
DESCRIPTION:tanruprubart\, phase 3\, Guillain-Barré Syndrome.\nStudy: An O
 pen Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as 
 ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)\nEst
 imated primary completion: 31 May 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tanruprubart#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07020819
URL:https://assetmemo.bio/drug/tanruprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06510816-5301@assetmemo.bio
DTSTAMP:20261121T010139Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Vonaprument: Phase 3 readout est. (NCT06510816)
DESCRIPTION:Vonaprument\, phase 3\, Age-Related Macular Degeneration.\nStud
 y: A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Inj
 ections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Rela
 ted Macular Degeneration (AMD) With Geographic Atrophy (GA)\nEstimated pri
 mary completion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/vonaprument#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06510816
URL:https://assetmemo.bio/drug/vonaprument#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07807969-5301@assetmemo.bio
DTSTAMP:20261121T010139Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Vonaprument: Phase 3 readout est. (NCT07807969)
DESCRIPTION:Vonaprument\, phase 3\, Age-Related Macular Degeneration.\nStud
 y: An Open-label Extension Study of the Long-Term Safety of Vonaprument (A
 NX007) in Participants With Dry Age-Related Macular Degeneration (AMD) Wit
 h Geographic Atrophy (GA)\nEstimated primary completion: 31 July 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/vonaprument#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07807969
URL:https://assetmemo.bio/drug/vonaprument#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
